VolitionRx Collaborates with Fujifilm Vet Systems for Canine Cancer Detection
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced a groundbreaking partnership with Fujifilm Vet Systems Co. Ltd, expanding its Nu.Q® Vet Cancer Test agreement. This collaboration will allow for a significant enhancement in the testing process for canine cancer. The expanded arrangement involves implementing Volition's chemiluminescent immunoassay (ChLIA) version for automated analysis via the Immunodiagnostic Systems (IDS) i10® platform. This innovative approach not only modernizes the testing process but is also expected to launch within five years.
Previously, Fujifilm Vet Systems provided the Nu.Q Vet Cancer Test in a manual format to veterinarians. Now, with this new automation capability, they aim to streamline cancer screenings for dogs in Japan. This marks an exciting time for both companies as they anticipate higher demand and quicker results in cancer diagnosis for pets.
Exciting Veterinary Insights from Leadership
Dr. Jasmine Kway, Chief Executive Officer of Volition, expressed enthusiasm about the collaboration. With an estimated seven million dogs in Japan, the market potential is vast. Dr. Kway noted, "We are ecstatic to extend our relationship with Fujifilm, bringing an automated solution to serve the growing needs of veterinary professionals and their canine patients. This venture will not only advance our technology but also enhance accessibility to timely cancer screenings."
Market Demand and Increased Vet Engagement
Kiyotaka Fujiwara, Chief Operating Officer at Fujifilm Vet Systems, commented on the interest from veterinary clinics in Japan since the initial launch of the Nu.Q® Vet Cancer Test. Over 1,000 veterinary hospitals have already registered to utilize the test, indicating a strong demand for automated cancer screening tools. "We are proud to be the first globally to implement centralized lab automation for this test, catering to the increasing appetite for rapid and efficient diagnostic services, thereby meeting veterinarian and pet owner expectations," Fujiwara stated.
Nu.Q® Vet Cancer Test: A Revolutionary Screening Tool
The Nu.Q® Vet Cancer Test is specifically designed for comprehensive health evaluations of dogs, particularly older dogs aged seven or above, and younger high-risk breeds. At a competitive cost of around $11 per test, it is a non-invasive procedure that can play a vital role in early cancer detection. Dr. Kway emphasized the importance of early diagnostics in enhancing the chances of successful treatment. Early cancer detection is a key factor in determining health outcomes for dogs, making this test an invaluable asset for veterinarians.
Technological Synergy in Veterinary Diagnostics
The automated lab platform used for the Nu.Q® Vet Cancer Test aligns with other human diagnostic tools developed by Volition, such as Nu.Q® Cancer and Nu.Q® Discover. This synergy exemplifies Volition's commitment to advancing the science of epigenetics and providing effective diagnostic solutions. The same technology that benefits human health is now being adapted for pet care, demonstrating Volition's dedication to improving health outcomes across species.
Future Prospects and Company Overview
The evolving partnership between Volition and Fujifilm Vet Systems exemplifies a forward-thinking approach to veterinary diagnostics. As this collaboration progresses and more data becomes available from the automated testing platform, both companies look forward to insights that could revolutionize animal health care. Volition, with its deep-rooted commitment to advancing epigenetic science, continues to delve into innovative solutions to combat life-threatening diseases across human and animal populations alike.
With research and development activities centered in Belgium and extended operations in the U.S. and London, Volition is strategically positioned to enhance its product offerings. Their subsidiary, Belgian Volition SRL, is aligned with these initiatives, ensuring that the Nu.Q® Vet Cancer Test reaches pet owners and veterinarians efficiently.
Frequently Asked Questions
What is the Nu.Q® Vet Cancer Test?
The Nu.Q® Vet Cancer Test is an advanced non-invasive screening tool designed for early detection of cancer in dogs, particularly benefiting older and high-risk breeds.
How does the automation of the Nu.Q test work?
The automation utilizes the Immunodiagnostic Systems (IDS) i10® platform, enhancing the efficiency of testing and accelerating the turnaround time for results.
Why is early detection of cancer important in dogs?
Early detection allows for timely treatment, which can significantly improve health outcomes and increase the chances of successful management of the disease.
Who is involved in the collaboration for the Nu.Q test?
The partnership involves VolitionRx Limited and Fujifilm Vet Systems, aiming to improve diagnostic capabilities within veterinary practices in Japan.
What are the benefits of the Nu.Q© Vet Cancer Test for veterinarians?
Veterinarians benefit from a reliable, quick, and accessible diagnostic tool, allowing them to provide better care and timely interventions for their canine patients.
